文献速递核素与放射性配体治疗肿瘤 PET/CT放射性药物与辐射防护

[177Lu]Lu-LNC1003在转移性去势抵抗性前列腺癌患者中的1期试验:确定最大耐受剂量与患者特异性剂量学

A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-10-21

这项1期试验纳入13例转移性去势抵抗性前列腺癌患者,采用标准3+3剂量递增方案评估[177Lu]Lu-LNC1003的1.11、1.85和2.59 GBq/周期三个剂量水平,每6周一次最多两周期。2.59 GBq时骨髓抑制为剂量限制性毒性,确定最大耐受剂量为1.85 GBq。全身有效剂量为0.35±0.05 mSv/MBq,唾液腺受照剂量最高(3.61±2.83 mSv/MBq),骨和淋巴结转移灶肿瘤平均吸收剂量分别为8.52和9.51 mSv/MBq。

要点

  • 2.59 GBq时骨髓抑制为剂量限制性毒性,最大耐受剂量确定为1.85 GBq。
  • 唾液腺预估辐射剂量最高(3.61±2.83 mSv/MBq),肾和红骨髓有效剂量分别为1.88±0.35和0.22±0.04 mSv/MBq。
  • 1.11 GBq/周期和1.85 GBq/周期多周期治疗耐受良好。

核心结论

  • 本1期试验显示[177Lu]Lu-LNC1003的最大耐受剂量为1.85 GBq。
  • 1.11 GBq/周期和1.85 GBq/周期多周期治疗耐受良好。
  • [177Lu]Lu-LNC1003在骨和淋巴结转移灶中具有较高的肿瘤有效剂量,未来更高剂量和多周期治疗研究中应密切监测红骨髓吸收剂量。
  • 给药频率也需进一步探索,以评估[177Lu]Lu-LNC1003治疗的疗效和副作用。

研究设计与样本

  • 这项转化研究为1期试验,纳入13例转移性去势抵抗性前列腺癌患者。
  • 采用标准3+3剂量递增方案,最终评估1.11、1.85和2.59 GBq/周期三个剂量水平。
  • 患者接受[177Lu]Lu-LNC1003治疗最多两周期,间隔6周。
  • 试验注册号NCT05613738,注册日期2022年11月14日。

主要发现

  • 患者接受[177Lu]Lu-LNC1003分次剂量为每周期1.11至2.59 GBq。
  • 2.59 GBq时骨髓抑制为剂量限制性毒性,1.85 GBq被确定为最大耐受剂量。
  • [177Lu]Lu-LNC1003全身有效剂量为0.35±0.05 mSv/MBq,唾液腺预估辐射剂量最高,为3.61±2.83 mSv/MBq。
  • 肾脏和红骨髓有效剂量分别为1.88±0.35和0.22±0.04 mSv/MBq,骨和淋巴结转移灶肿瘤平均吸收剂量分别为8.52和9.51 mSv/MBq。
  • 第一周期治疗后,剂量水平1(1.11 GBq)、2(1.85 GBq)、3(2.59 GBq)分别有1例(33.3%)、4例(66.7%)、2例(50.0%)患者出现PSA下降;第二周期后,剂量水平1有1例(33.3%)、剂量水平2有4例(66.6%)患者较基线血清PSA值出现PSA下降。

关键数值与推荐

  • 最大耐受剂量为1.85 GBq/周期。
  • 剂量限制性毒性为2.59 GBq时的骨髓抑制。
  • 全身有效剂量0.35±0.05 mSv/MBq;唾液腺3.61±2.83 mSv/MBq;肾脏1.88±0.35 mSv/MBq;红骨髓0.22±0.04 mSv/MBq。
  • 骨转移灶肿瘤平均吸收剂量8.52 mSv/MBq;淋巴结转移灶9.51 mSv/MBq。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 红骨髓吸收剂量在未来更高剂量和多周期治疗研究中应密切监测。
  • 给药频率需进一步探索以评估疗效和副作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This translational study aimed to determine the maximum tolerated dose (MTD), safety, dosimetry, and therapeutic efficacy of 177Lu-PSMA-EB-01 (denoted as [177Lu]Lu-LNC1003) in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: A total of 13 patients with mCRPC were recruited in this study. A standard 3 + 3 dose escalation protocol was performed. The following dose levels were ultimately evaluated: 1.11, 1.85, and 2.59 GBq/cycle. Patients received [177Lu]Lu-LNC1003 therapy for up to two cycles at a 6-week interval. RESULTS: Patients received fractionated doses of [177Lu]Lu-LNC1003 ranging from 1.11 to 2.59 GBq per cycle. Myelosuppression was dose-limiting at 2.59 GBq, and 1.85 GBq was determined to be the MTD. The total-body effective dose for 177Lu-LNC1003 was 0.35 ± 0.05 mSv/MBq. The salivary glands were found to receive the highest estimated radiation dose, which was calculated to be 3.61 ± 2.83 mSv/MBq. The effective doses of kidneys and red bone marrow were 1.88 ± 0.35 and 0.22 ± 0.04 mSv/MBq, respectively. The tumor mean absorbed doses for bone and lymph node metastases were 8.52 and 9.51 mSv/MBq. Following the first treatment cycle, PSA decline was observed in 1 (33.3%), 4 (66.7%), and 2 (50.0%) patients at dose levels 1 (1.11 GBq), 2 (1.85 GBq), and 3 (2.59 GBq), respectively. Compared with the baseline serum PSA value, 1 (33.3%) at dose level 1 and 4 (66.6%) patients at dose level 2, presented a PSA decline after the second treatment cycle. CONCLUSION: This phase 1 trial revealed that the MTD of [177Lu]Lu-LNC1003 is 1.85 GBq. The treatment with multiple cycles at the dose of 1.11 GBq /cycle and 1.85 GBq /cycle was well tolerated. [177Lu]Lu-LNC1003 has higher tumor effective doses in bone and lymph nodes metastases while the absorbed dose in the red bone marrow should be closely monitored in future treatment studies with higher doses and multiple cycles. The frequency of administration also needs to be further explored to assess the efficacy and side effects of [177Lu]Lu-LNC1003 treatment. TRIAL REGISTRATION: 177Lu-PSMA-EB-01 in patients with metastatic castration-resistant prostate cancer (NCT05613738, Registered 14 November 2022). URL of registry https://classic. CLINICALTRIALS: gov/ct2/show/NCT05613738.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zang J, Wang G, Zhao T, et al. A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2023. PMID: 37864592. doi:10.1007/s00259-023-06470-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。